Pemphigus Foliaceus
Pemphigus foliaceus is an autoimmune blistering disease characterized by the presence of autoantibodies against desmoglein-1 (Dsg1), a protein responsible for maintaining epidermal intercellular adhesion. Our company is at the forefront of these advancements, offering comprehensive services in pemphigus foliaceus drug and therapy development.
Overview of Pemphigus Foliaceus
Pemphigus foliaceus is a rare autoimmune disease that primarily affects the skin. It is characterized by the presence of superficial blisters and erosions, often accompanied by crusting and scaling. The pathogenesis of pemphigus foliaceus involves the production of autoantibodies against desmoglein-1, a protein that plays a crucial role in maintaining the integrity of the epidermis. These autoantibodies bind to desmoglein-1, leading to the activation of proteases and subsequent loss of adhesion between epidermal cells. This results in the formation of superficial blisters and erosions characteristic of pemphigus foliaceus.
Fig.1 Representative case of histopathological analysis of pemphigus foliaceus. (Pham N. N., et al., 2023)
Drug Discovery and Development for Pemphigus Foliaceus
The development of effective drugs and therapies for pemphigus foliaceus is aimed at suppressing the autoimmune response and restoring the integrity of the skin. Corticosteroids, such as prednisone or prednisolone, are the mainstay of therapeutic for pemphigus foliaceus. Adjuvant therapies are often used in conjunction with corticosteroids to enhance therapeutic outcomes and reduce the required dose of corticosteroids. In cases where standard therapies are not effective or contraindicated, other therapeutic options can be considered. Hydroxychloroquine, dapsone, methotrexate, intravenous immunoglobulin, and rituximab have shown potential in managing refractory pemphigus foliaceus.
We invite you to explore the provided link to delve deeper into the comprehensive array of platforms we have developed. Each platform is thoughtfully crafted to address specific therapeutic needs, empowering us to deliver innovative and effective solutions.
Small Molecule Drug
Probiotics Therapy
Therapeutic Antibody
Cell Therapy
Gene Therapy
Therapeutics Development
Our Services
As a leading company in the field of autoimmune disease research and development, our company offers comprehensive diagnostics and therapy development services for pemphigus foliaceus. Animal models and in vitro models play a crucial role in understanding disease mechanisms and evaluating potential therapies. We specialize in the development of pemphigus foliaceus animal models and in vitro models, enabling researchers to test the efficacy and safety of potential drugs and therapies in a controlled environment.
Passive Transfer Models
Passive transfer models involve the transfer of pathogenic autoantibodies from PF patients or animal donors to recipient animals, allowing the study of disease progression and potential therapeutic interventions. At our company, we offer a comprehensive range of passive transfer model development services for PF research.
Immunization-Based Active Models
Active models of PF involve inducing the production of autoantibodies against DSG1 in animals. One commonly employed approach is immunizing animals, such as mice, with recombinant DSG1 protein to induce an immune response and the subsequent production of autoantibodies.
Our company focuses on developing robust and reproducible primary keratinocyte culture models, as well as developing co-culture models to accurately reproduce the complex interactions between keratinocytes and immune cells in PF.
Organ-on-a-chip models consist of microfluidic devices that incorporate multiple cell types, providing a platform to simulate the dynamic interactions between cells, blood vessels, and immune responses.
Why Choose Us?
Our preclinical research services provide a comprehensive evaluation of the safety and pharmacokinetics of potential drugs and therapies for pemphigus foliaceus. In addition to the aforementioned range of services and models, we also specialize in tailoring customized solutions and developing disease models that precisely align with your distinctive requirements. Should our array of services capture your interest, we warmly encourage you to reach out to us without hesitation.
Reference
- Pham N. N., et al. "Pemphigus Foliaceus after COVID‐19 Vaccination: A Report of Two Cases." Case Reports in Dermatological Medicine 2023.1 (2023): 1218388.